Nordion Stock Rating Upgraded by RBC Capital (NDZ)
Shares of Nordion opened at 6.92 on Thursday. Nordion has a one year low of $5.51 and a one year high of $10.96. The stock’s 50-day moving average is currently $6.92. The company’s market cap is $428.4 million.
Nordion last released its earnings data on Tuesday, March 5th. The company reported $0.07 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.03 by $0.04. The company had revenue of $53.70 million for the quarter, compared to the consensus estimate of $53.01 million. On average, analysts predict that Nordion will post $0.53 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at TheStreet upgraded shares of Nordion from a “sell” rating to a “hold” rating in a research note to investors on Thursday. Separately, analysts at CIBC reiterated a “sector perform” rating on shares of Nordion in a research note to investors on Monday. They now have a $8.00 price target on the stock.
Two research analysts have rated the stock with a buy rating, three have given a hold rating, and one has given a sell rating to the stock. The company presently has a consensus rating of “hold” and a consensus price target of $8.53.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global specialty health science company that provides market-leading products and services used for the prevention, diagnosis and treatment of disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.